RGJ.com: Macular degeneration: Help's in sight, but at what cost?

This feature about lucentis vs avastin for macular degeneration in the local Reno paper, demonstrates the need for precision in speaking with the media. All the direct quotes attributed to me have a "folksy" feel, as though the interviewer had the preconceived notion to "paint" me as a local country doctor. I don't remember speaking as informally as I was quoted. But the article presented a fairly balanced view of the debate, notwithstanding the unsubstantiated claims by Genentech that avastin is "not as pure" as lucentis and the claim that lucentis is less inflammatory then avastin...

My only other beef with the article is that the author chose not to highlight the fact that we offer 360 macular rotation surgery here and have had some impressive improvemnts in vision...

RGJ.com: Macular degeneration: Help's in sight, but at what cost?: "Several questions about cost and the manufacturer's motives are dampening enthusiasm for the first approved drug that reverses a potentially devastating eye disease seen in the elderly."